DE-PHARMA: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
DE-PHARMA
Largest movements
- Cash -€150,424
down €150,424 (-13.2%), from €1.1m to €990,695
mainly Investment in fixed assets (net) (-€210,972) and Deferred charges and accrued income (-€11,555)
- Tangible fixed assets +€147,429
up €147,429 (+60.2%), from €244,766 to €392,196
of which Plant, machinery and equipment: +€190,469
No liability line moved by more than 1% of the balance sheet total.
- Gross operating margin -€29,304
down €29,304 (-27.8%), from €105,375 to €76,071
- Taxes -€13,217
down €13,217 (-79.2%), from €16,687 to €3,470
- Depreciation +€9,834
up €9,834 (+18.3%), from €53,708 to €63,542
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €1,600,143 | €1,602,364 | +€2,221 | +0.1% |
| Fixed assets | 21/28 | €244,766 | €392,196 | +€147,429 | +60.2% |
| Tangible fixed assets | 22/27 | €244,766 | €392,196 | +€147,429 | +60.2% |
| Land and buildings | 22 | €194,400 | €151,360 | -€43,040 | -22.1% |
| Plant, machinery and equipment | 23 | €50,366 | €240,836 | +€190,469 | +378.2% |
| Current assets | 29/58 | €1,355,377 | €1,210,168 | -€145,208 | -10.7% |
| Amounts receivable within one year | 40/41 | €213,013 | €206,674 | -€6,339 | -3.0% |
| Trade receivables | 40 | €17,840 | €8,619 | -€9,221 | -51.7% |
| Other amounts receivable | 41 | €195,173 | €198,055 | +€2,883 | +1.5% |
| Cash at bank and in hand | 54/58 | €1,141,119 | €990,695 | -€150,424 | -13.2% |
| Deferred charges and accrued income | 490/1 | €1,245 | €12,799 | +€11,555 | +928.4% |
| Total equity and liabilities | 10/49 | €1,600,143 | €1,602,364 | +€2,221 | +0.1% |
| Equity | 10/15 | €1,210,846 | €1,219,846 | +€9,000 | +0.7% |
| Contributions | 10/11 | €62,272 | €62,272 | = | 0.0% |
| Capital | 10 | €62,272 | €62,272 | = | 0.0% |
| Issued capital | 100 | €62,272 | €62,272 | = | 0.0% |
| Reserves | 13 | €1,064,149 | €1,073,149 | +€9,000 | +0.8% |
| Non-distributable reserves | 130/1 | €27,800 | €27,800 | = | 0.0% |
| Legal reserve | 130 | €27,800 | €27,800 | = | 0.0% |
| Distributable reserves | 133 | €1,036,349 | €1,045,349 | +€9,000 | +0.9% |
| Profit (loss) carried forward | 14 | €84,425 | €84,425 | = | 0.0% |
| Amounts payable | 17/49 | €389,297 | €382,518 | -€6,778 | -1.7% |
| Amounts payable within one year | 42/48 | €384,872 | €382,518 | -€2,354 | -0.6% |
| Current portion of amounts payable after more than one year | 42 | €0 | - | = | |
| Trade debts | 44 | €0 | €557 | +€557 | |
| Suppliers | 440/4 | €0 | €557 | +€557 | |
| Taxes, remuneration and social security | 45 | €16,260 | €11,686 | -€4,574 | -28.1% |
| Taxes | 450/3 | €16,260 | €11,686 | -€4,574 | -28.1% |
| Other amounts payable | 47/48 | €368,613 | €370,276 | +€1,663 | +0.5% |
| Accrued charges and deferred income | 492/3 | €4,424 | €0 | -€4,424 | -100.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €53,708 | €63,542 | +€9,834 | +18.3% |
| Other operating charges | 640/8 | €38 | - | -€38 | |
| Gross operating margin | 9900 | €105,375 | €76,071 | -€29,304 | -27.8% |
| Operating profit (loss) | 9901 | €51,628 | €12,528 | -€39,100 | -75.7% |
| Financial income | 75/76B | €4 | €144 | +€140 | +3886.7% |
| Recurring financial income | 75 | €4 | €144 | +€140 | +3886.7% |
| Financial charges | 65/66B | €671 | €202 | -€469 | -69.9% |
| Recurring financial charges | 65 | €671 | €202 | -€469 | -69.9% |
| Profit (loss) for the period before taxes | 9903 | €50,961 | €12,470 | -€38,491 | -75.5% |
| Income taxes | 67/77 | €16,687 | €3,470 | -€13,217 | -79.2% |
| Profit (loss) for the period | 9904 | €34,274 | €9,000 | -€25,275 | -73.7% |
| Profit (loss) for the period to be appropriated | 9905 | €34,274 | €9,000 | -€25,275 | -73.7% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 30 September 2026 via checked.be.